acquisition
Metsera, Inc.Pfizer Inc.
- Target
- Metsera, Inc.
- Acquirer or investor
- Pfizer Inc.
Structure
Not a psychedelic deal. Row exists so the CVR can be tied to its instrument identifier for the CVR-holder work (the cvr-market folder on the bus). Issuer of the CVR: Pfizer Inc. (acquirer). Origin: Pfizer's acquisition of Metsera, Inc., completed 2025-11-13 under the Agreement and Plan of Merger dated 2025-09-21, as amended by Amendment No. 1 dated 2025-11-07. Instrument identifier: CUSIP 592CVR013, ISIN US592CVR0133, N-PORT in-house asset ID 1543698. SOURCE 1 (source_url), read from the filing itself 2026-11-05: Form N-PORT accession 0002071691-26-001203, registrant Putnam Asset Allocation Funds (CIK 914209), series Putnam Multi-Asset Income Fund S000067964, report date 2025-11-30: the holding with <cusip>592CVR013</cusip> has <name> and <title> 'Metsera, Inc.', 105 NS, valUSD 514.50, assetCat OTHER desc 'Right', fair value level 3, restricted. SOURCE 2: Pfizer Form 8-K accession 0000078003-25-000159 (CIK 78003), filed and period 2025-11-13, Item 8.01 Results of Other Events, https://www.sec.gov/Archives/edgar/data/78003/000007800325000159/pfe-20251113.htm : completion of the Metsera acquisition on 2025-11-13; each share converted into $65.60 cash at closing, enterprise value approximately $7.0 billion, and one non-transferable CVR for up to $20.65 per share on three milestones: $4.60 on initiation of the Phase 3 trial of the MET-097i + MET-233i combination, $6.40 on FDA approval of monthly MET-097i monotherapy, $9.65 on FDA approval of the monthly MET-097i + MET-233i combination. The 8-K does not print the CUSIP. SOURCE 3, ties the issuer name to the same CUSIP: Form N-PORT accession 0002071691-26-024883 (CIK 914209), series Franklin Multi-Asset Income Fund S000067964, report date 2026-08-31, https://www.sec.gov/Archives/edgar/data/914209/000207169126024883/primary_doc.xml : <name> 'Pfizer, Inc.', <title> 'Pfizer, Inc., CVR', <cusip>592CVR013</cusip>, same ISIN, same in-house asset ID 1543698, 105 NS, valUSD 514.50. The link CUSIP to Metsera CVR therefore rests on Source 1 (names Metsera under the CUSIP) and Source 3 (names Pfizer, Inc., CVR under the same CUSIP and asset ID); Source 2 supplies the closing date and CVR terms. Those two N-PORTs are one series filed under two names. The 8-K calls the CVR non-transferable; the N-PORT CUSIP is the funds' own pricing-vendor identifier for the right, not evidence of a tradable security. upfront_usd_m, contingent_usd_m and total_headline_usd_m left blank: the 8-K gives per-share figures and an enterprise value, not aggregate equity or CVR dollar totals. No FX: all amounts USD. Asset id and company rows for Metsera deliberately not added in this change. Supersedes the D007 row of 2026-11-05 (kept): no fact changed; the notes drop an internal file path that the site's leak check refuses on a rendered page (10 Nov 2026).
Why it matters
Ties the N-PORT line 'Pfizer, Inc., CVR', CUSIP 592CVR013, to the Metsera CVR, so a blind check has a row and a URL to open instead of relying on memory. Not a psychedelic deal.
Sourcing
- Source type
- sec_filing
- Verified
- 5 November 2026
- Confidence
- verified